# A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis

> **NCT07265284** · PHASE3 · RECRUITING · sponsor: **Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.** · enrollment: 104 (estimated)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** IBI112
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT07265284
- **Lead sponsor:** Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-03
- **Primary completion:** 2026-09-30
- **Final completion:** 2029-01-31
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07265284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07265284, "A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07265284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*